SCHEDULE OF STOCK WARRANT ACTIVITY (Details) - Warrant [Member] - $ / shares |
9 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Number of warrants, outstanding and exercisable, beginning balance | 1,455,119 | 1,455,119 |
Weighted average exercise price, outstanding and exercisable, beginning balance | $ 6.10 | $ 6.10 |
Number of warrants, warrants issued | 41,196 | |
Weighted average exercise price, warrants issued | $ 3.24 | |
Number of warrants, warrants exercised | (83,205) | |
Weighted average exercise price, warrants exercised | $ 4.00 | |
Number of warrants, outstanding and exercisable, ending balance | 1,413,110 | 1,455,119 |
Weighted average exercise price, outstanding and exercisable, ending balance | $ 6.14 | $ 6.10 |
Weighted average remaining contract term warrants outstanding and exercisable | 2 years 8 months 23 days | 3 years 5 months 23 days |
X | ||||||||||
- Definition Weighted Average Exercise Price Per Warrant outstanding and exercisable, balance. No definition available.
|
X | ||||||||||
- Definition Weighted average exercise price nonoption exercised. No definition available.
|
X | ||||||||||
- Definition Weighted Average Exercise Price Per Warrant, issued. No definition available.
|
X | ||||||||||
- Definition Remaining Contract Term (years) Warrants outstanding and exercisable. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|